Pharmaceuticals Johnson & Johnson Enters into Agreement to Acquire Yellow Jersey Therapeutics for $1.25 Billion in All Cash Transaction Last updated: July 11, 2024 3:44 pm By bexib 0 Min Read Share SHARE The acquisition of Yellow Jersey Therapeutics includes access to NM26, a potential treatment for atopic dermatitis. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article Weekly initial unemployment claims fall to 222,000 Next Article What is TapSwap? Discover this play and earn game – Investorempires.com Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Selfridges ringing in the new year on the roof of San Carlo’s Alto Hospitality & Tourism Season 2024: Exceeding expectations at Borghese Contemporary Hotel Hospitality & Tourism JPMorgan and Bank of America respond to CFPB lawsuit Banking Zell says CFPB lawsuit against big banks is ‘regulatory overreach’ Banking